BIOCRYST PHARMACEUTICALS INC (BCRX) — Institutional Holders, Q2 2026 (page 4)

319 institutional investment managers reported a BCRX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $2.6B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 301 to 319. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

BCRX 13F holders ranked 301–319 of 319

Institutional investors reporting a position in BIOCRYST PHARMACEUTICALS INC on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Bare Financial Services#301 · 148 sh$1.5K0.0%
Basecamp Wealth Advisors#302 · 133 sh$1.3K+133.3%
Bell Investment Advisors#303 · 107 sh$1.1K0.0%
Oakworth Capital#304 · 100 sh$1.0K-90.4%
Wealth Enhancement Services#305 · 98 sh$980.00New
Cornerstone Planning Group#306 · 100 sh$951.000.0%
Parallel Advisors#307 · 90 sh$900.00+76.5%
Global Retirement Partners#308 · 70 sh$700.00—
SBI Securities , Ltd.#309 · 70 sh$700.00-78.8%
HARBOUR INVESTMENTS#310 · 52 sh$520.000.0%
Keating Financial Advisory Services#311 · 48 sh$480.00-28.4%
Cornerstone Financial Management#312 · 46 sh$460.000.0%
Key FInancial#313 · 38 sh$380.000.0%
Silver Grove Financial Group#314 · 15 sh$150.00New
VALLEY NATIONAL ADVISERS#315 · 10 sh$100.00New
Dunhill Financial#316 · 2 sh$22.000.0%
Hughes Financial Services#317 · 2 sh$20.000.0%
DANSKE BANK A/S#318 · 2 sh$20.000.0%
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#319 · 251,230 sh—-2.8%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.